Willingness to use HIV pre-exposure prophylaxis among opiate users

AIDS Behav. 2014 Sep;18(9):1694-700. doi: 10.1007/s10461-014-0778-z.

Abstract

Few studies of pre-exposure prophylaxis (PrEP) to prevent HIV infection have focused on drug users. Between February to September 2013, we asked 351 opiate injectors entering detoxification treatment about HIV risk, knowledge about PrEP, and willingness to use a once daily PrEP pill under one of two randomly assigned effectiveness scenarios-40 % (low) or 90 % (high) effective in reducing HIV risk. Participants were 70 % male and 87 % non-Hispanic White. Only 7 % had heard of a drug to reduce HIV risk, yet once informed, 47 % would be willing to take such a pill [35 % of those in the low effectiveness scenario and 58 % in the high group (p < 0.001)]. Higher perceived HIV risk was associated with greater willingness to take medication. Increasing knowledge of PrEP and the rate of HIV reduction-effectiveness promised will influence its use among targeted high-risk drug users.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Oral
  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use
  • Female
  • HIV Infections / complications
  • HIV Infections / prevention & control*
  • HIV Infections / virology
  • Health Knowledge, Attitudes, Practice*
  • Health Surveys
  • Humans
  • Male
  • Massachusetts
  • Opioid-Related Disorders / complications*
  • Opioid-Related Disorders / therapy
  • Patient Acceptance of Health Care / statistics & numerical data*
  • Pre-Exposure Prophylaxis / methods*
  • Risk Factors
  • Socioeconomic Factors
  • Substance Abuse Treatment Centers
  • Substance Abuse, Intravenous / complications*
  • Substance Abuse, Intravenous / therapy
  • Surveys and Questionnaires
  • Young Adult

Substances

  • Anti-HIV Agents